![]() | ![]() |
Strides Pharma Reports 21.3 Percent Growth in US Revenue in 9MFY25
The gross margin stood at INR 6,735 million, marking a 25.1 percent rise compared to the same quarter last year.
Strides Pharma Science | 31/01/2025 | By Aishwarya
Strides Gets Approval from Equity Shareholders for Launch of OneSource
This is a critical step in the creation of OneSource and the support from Shareholders and Secured Creditors underscores the confidence in the company’s strategic initiative to create OneSource - India’s first specialty pharma Contract Development and Manufacturing Organization (CDMO).
Strides Pharma Science | 11/09/2024 | By Aishwarya | 269
Strides Pharma Receives FDA Approval for Antidepressant Drug
Strides Pharma Science’s subsidiary has gained approval from the US health regulator to market a generic antidepressant medication.
Strides Pharma Science | 10/04/2024 | By Aishwarya | 367
Strides Gets USFDA Approval for Mycophenolate Mofetil for Oral Suspension
The company has 280 cumulative ANDA filings with USFDA.
Strides Pharma Science | 31/08/2023 | By Manvi | 478
Strides flagship facility in Bengaluru receives US FDA inspection closure
The company's flagship facility was inspected by the US FDA between December 5 and 9, 2022, and a form 483 listing three inspectional observations was issued
Strides Pharma Science | 24/02/2023 | By Sudeep Soparkar | 394
Strides Pharma completes WHO PQ inspection at Puducherry facility
The inspection was carried out between January 16-20, 2023
Strides Pharma Science | 23/01/2023 | By Sudeep Soparkar | 553
Strides Pharma's Bengaluru facility receives EIR from US FDA
The abbreviated Quality System Inspection Technique (QSIT) drug pre-approval on-site inspection was specifically conducted by the US FDA
Strides Pharma Science | 18/01/2023 | By Sudeep Soparkar | 283
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy